JNJ-75276617
- Generic Name
- JNJ-75276617
- Drug Type
- Small Molecule
- Background
JNJ-75276617 is under investigation in clinical trial NCT05453903 (A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies).
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2025-02-28
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 600
- Registration Number
- NCT06852222
- Locations
- 🇮🇱
Hadassah University Hospita Ein Kerem, Jerusalem, Israel
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
- Conditions
- Acute LeukemiasAcute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- Drug: Intrathecal Chemotherapy
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05521087
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT05453903
- Locations
- 🇪🇸
Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain
🇪🇸Hosp Clinic de Barcelona, Barcelona, Spain
🇪🇸Hosp Univ Vall D Hebron, Barcelona, Spain
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAcute LeukemiasAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 400
- Registration Number
- NCT04811560
- Locations
- 🇪🇸
Hosp. Clinico Univ. de Valencia, Valencia, Spain
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.